Reply  by Lip, Gregory Y.H. et al.
RP
A
S
L
B
t
R
596 Correspondence JACC Vol. 61, No. 5, 2013
February 5, 2013:594–7*Affiliated Hospital of Medical College
Qingdao University
Neurology
No. 16 Jiangsu Road
Qingdao, Shandong 266003
China
E-mail: drlhf@163.com
http://dx.doi.org/10.1016/j.jacc.2012.08.1028
EFERENCES
1. Lip GY, Larsen TB, Skjoth F, Rasmussen LH. Indirect comparisons of
new oral anticoagulant drugs for efficacy and safety when used for stroke
prevention in atrial fibrillation. J Am Coll Cardiol 2012;60:738–46.
2. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxa-
ban and apixaban for atrial fibrillation. Thromb Haemost 2012;108:
476–84.
3. Schneeweiss S, Gagne JJ, Patrick AR, Choudhry NK, Avorn J.
Comparative efficacy and safety of new oral anticoagulants in patients
with atrial fibrillation. Circ Cardiovasc Qual Outcomes 2012;5:480–6.
4. Rothwell PM, Algra A, Amarenco P. Medical treatment in acute and
long-term secondary prevention after transient ischaemic attack and
ischaemic stroke. Lancet 2011;377:1681–92.
5. Kirshner HS. Differentiating ischemic stroke subtypes: risk factors and
secondary prevention. J Neurol Sci 2009;279:1–8.
6. Hankey GJ, Patel MR, Stevens SR, et al., for the ROCKET-AF
Steering Committee Investigators. Rivaroxaban compared with warfarin
in patients with atrial fibrillation and previous stroke or transient
ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol
2012;11:315–22.
Reply
We thank Drs. Li and Zhao for their interest in our paper
(1). They are correct that indirect comparisons cannot address all
the heterogeneity between trials, as well as the underlying patho-
genic mechanisms that they allude to. However, it is not very likely
that there would be major differences in stroke subtypes among the
3 studies. Also, the inclusion and exclusion criteria are broadly the
same in the 3 trials, except for the ROCKET-AF (Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Compared With
Vitamin K Antagonism for Prevention of Stroke and Embolism
Trial in Atrial Fibrillation) trial, wherein more patients may
possibly have a different stroke type than thromboembolism-
related, because of the higher-risk profile.
The only way to definitively address this issue would be to
perform a large head-to-head randomized trial, and with the
current agents, this would need to be a 4-arm noninferiority
randomized trial of dabigatran (2 doses), apixaban, and rivaroxa-
ban, which would probably require a massive number of atrial
fibrillation patients (probably 50,000) and require 5 years of
follow-up.
In the absence of head-to-head comparisons, indirect compar-
isons allow the opportunity to have some insight into how these
novel anticoagulants would perform against each other for the
main efficacy and safety endpoints (2). To that end, our analysis (1)
concludes that there are no profound differences in the major
efficacy and safety endpoints between the novel oral anticoagulants.
This is consistent with other recent papers on the same topic (3,4),
although 1 analysis by Kansal et al. (5) did highlight some
differences with fewer incidents of ischaemic stroke and intracra-
nial hemorrhage, as well as cost effectiveness, when dabigatran was
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Not All Fat Is Equal
We read with interest the paper by Gupta et al. (1). Adipose tissue
is a major source of hormones and cytokines implicated in systemic
inflammatory reactions, metabolic abnormalities, hypertension,
and insulin resistance (2,3). The investigators use body mass index
(BMI) to classify adiposity status. However, it is useful to
re-evaluate how body fat is determined. Numerous studies have
produced evidence that BMI has limited ability to accurately
predict body composition.
So how fat is fat? BMI is the most commonly used measure to
determine adiposity status in everyday clinical practice. It is a safe,
convenient, and popular method. However, the index is an indirect
surrogate of body fat, which is not able to distinguish lean body
mass from fat mass. There is growing body of evidence that BMI
may misclassify weight status in many patients (4–6). It tends to
overestimate normal weight and underestimate overweight or
obesity.
Dual-energy X-ray (DXA) absorptiometry is considered by
many to be a gold standard for assessing body composition (direct
measurement of total body fat and lean soft tissue mass). It
provides a more accurate indication of body fat percentage, which
is one of the fundamental links between obesity and its associated
disease risk.
